News & Literature

• Feb 22, 12 Regado Biosciences, Inc. to Present at the Citi 2012 Global Health Care Conference in New York, NY
• Nov 14, 11 Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR trial for REG1, its lead product candidate, at the American Heart Association (AHA) Scientific Sessions 2011 Meeting
• Nov 07, 11 Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
• Sep 28, 11 Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
• Sep 14, 11 Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
• Apr 03, 11 Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
• Mar 30, 11 Regado Biosciences to Present at the Needham & Company’s 10th Annual Healthcare Conference in New York City
• Mar 28, 11 Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA
• Feb 23, 11 Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
• Nov 23, 10 Regado Biosciences to Present at the 22nd Annual Piper Jaffray Health Care Conference in New York City and the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference in San Francisco
• Nov 17, 10 Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
• Nov 16, 10 Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results from its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
• Nov 15, 10 Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and part of the REG2 Anticoagulant System, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
• Nov 03, 10 Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
• Nov 03, 10 Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
• Nov 02, 10 Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
• Oct 29, 10 Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
• Sep 16, 10 Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
• Sep 09, 10 Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
• Jul 27, 10 Regado Biosciences to Present at the 2010 Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference
• Jul 26, 10 Regado Biosciences Announces Publication in the American Heart Association Journal Circulation of the Results of a Phase 2a Study for the REG1 Anticoagulant System in Elective Percutaneous Interventions
• Jun 17, 10 Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
• Jun 08, 10 Regado Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference in New York City on June 11, 2010
• Jun 07, 10 Regado Biosciences to Present at the 9th Annual Needham Healthcare Conference on June 10, 2010 in New York City
• May 25, 10 Regado Biosciences, Inc. Continues to Expand its Patent Portfolio by Announcing Issuance of a New Patent for its Product Candidates, the REG1 and REG2 Anticoagulation Systems
• Apr 30, 10 Regado Biosciences to Present at the Bio International Convention Held in Chicago, Illinois on May 5, 2010
• Apr 09, 10 Regado Biosciences, Inc. Presents the First Clinical Experience with REG2, Its Second Product Candidate
• Mar 15, 10 Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference
• Dec 17, 09 Regado Biosciences, Inc. Completes $40 Million Series D Financing
• Nov 25, 09 Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
• Nov 12, 09 Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
• Nov 11, 09 Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
• Nov 10, 09 Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
• Nov 03, 09 Regado Biosciences to Present at the 3rd Annual Canaccord Adams Cardiovascular Conference on November 10, 2009
• Oct 27, 09 Regado Biosciences to Present at the BIO-Europe Conference 2009 on November 3, 2009
• Oct 22, 09 Regado Biosciences to Present at the 8th Annual BIO Investor Forum on October 29, 2009
• Oct 05, 09 Regado Biosciences to Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
• Sep 17, 09 Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
• Sep 15, 09 Regado Biosciences to Present at the Biopharm America 2009 Conference on September 17, 2009
• Sep 09, 09 REGADO BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN RADAR (Phase 2b) STUDY OF REG1 ANTICOAGULATION SYSTEM
• Sep 04, 09 REGADO BIOSCIENCES TO PRESENT AT THE THOMAS WEISEL PARTNERS HEALTHCARE CONFERENCE 2009 ON SEPTEMBER 11, 2009
• Sep 03, 09 REGADO BIOSCIENCES TO PRESENT AT THE RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 10, 2009
• Aug 31, 09 REGADO BIOSCIENCES RELEASES POSITIVE PHASE 2A DATA FOR THE REVERSIBLE ANTICOAGULANT SYSTEM REG1 AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS IN BARCELONA, SPAIN
• Aug 24, 09 REGADO BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 1 STUDY OF SUBCUTANEOUSLY ADMINISTERED REG1 ANTICOAGULATION SYSTEM
• Jul 20, 09 REGADO BIOSCIENCES EXPANDS MEDICAL ADVISORY BOARD
• Jun 02, 09 REGADO BIOSCIENCES ESTABLISHES MEDICAL ADVISORY BOARD
• Mar 30, 09 REGADO BIOSCIENCES TO PRESENT AT THE 16TH ANNUAL FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE
• Mar 17, 09 REGADO BIOSCIENCES SELECTED TO PRESENT AT INSIDEVENTURE’S DEBUT INVESTOR CONFERENCE – MARCH 25-26, SANTA BARBARA, CALIFORNIA
• Feb 12, 09 REGADO BIOSCIENCES TO PRESENT AT THE 2009 WHARTON HEALTHCARE BUSINESS CONFERENCE
• Jan 15, 09 DR. STEVEN L. ZELENKOFSKE JOINS REGADO BIOSCIENCES AS SENIOR VICE PRESIDENT, CLINICAL AND MEDICAL AFFAIRS AND CHIEF MEDICAL OFFICER
• Jan 06, 09 REGADO BIOSCIENCES TO PRESENT AT THE 27TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
• Dec 02, 08 ELLEN MCDONALD JOINS REGADO BIOSCIENCES AS SENIOR VICE PRESIDENT OF BUSINESS OPERATIONS AND CHIEF BUSINESS OFFICER
• Dec 01, 08 REGADO BIOSCIENCES TO PRESENT AT THE PIPER JAFFRAY HEALTH CARE CONFERENCE ON TUESDAY, DECEMBER 2, 2008
• Nov 11, 08 ALEXANDER R. GIAQUINTO, PH.D., JOINS REGADO BIOSCIENCES AS SENIOR VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY ASSURANCE
• Oct 14, 08 REGADO BIOSCIENCES COMPLETES PATIENT ENROLLMENT FOR PHASE IIA STUDY OF REG1 ANTICOAGULATION SYSTEM
• Sep 02, 08 REGADO BIOSCIENCES REPORTS CLINICAL RESULTS FOR REG1 ANTICOAGULATION SYSTEM AT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2008
• Aug 04, 08 DAVID J. MAZZO, PH.D., JOINS REGADO BIOSCIENCES AS PRESIDENT AND CEO
• Jun 05, 08 REGADO BIOSCIENCES ANNOUNCES PUBLICATION IN CIRCULATION OF CLINICAL TRIAL RESULTS OF REG1 ANTICOAGULATION SYSTEM
• May 14, 08 REGADO BIOSCIENCES’ REG1 ANTICOAGULATION SYSTEM STUDY RESULTS PUBLISHED IN THE JOURNAL OF THROMBOSIS AND HAEMOSTASIS
• Nov 06, 07 REGADO BIOSCIENCES PRESENTS PHASE I DATA FOR REG1 ANTICOAGULATION SYSTEM AT AMERICAN HEART ASSOCIATION 2007 SCIENTIFIC SESSIONS
• Nov 04, 07 REGADO BIOSCIENCES PRESENTS POSITIVE DATA FROM REG1 ANTICOAGULATION SYSTEM PHASE Ic STUDY AT AMERICAN HEART ASSOCIATION 2007 SCIENTIFIC SESSIONS
• Mar 27, 07 REGADO BIOSCIENCES COMPLETES $23 MILLION SERIES C FINANCING

• Press Releases
• Publications & Presentations